Coherus Oncology (CHRS) Cash from Operations Growth (1y) (2014 - 2026)
Coherus Oncology (CHRS) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Coherus Oncology |
199.14 Mn |
32.09 Mn |
8.50 Mn |
-124.14% |
| Date | Value |
|---|
| Mar 31, 2026 |
-124.14% |
| Dec 31, 2025 |
-168.92% |
| Sep 30, 2025 |
25.28% |
| Jun 30, 2025 |
-178.07% |
| Mar 31, 2025 |
44.78% |
| Dec 31, 2024 |
321.13% |
| Sep 30, 2024 |
-14.21% |
| Jun 30, 2024 |
253.50% |
| Mar 31, 2024 |
31.96% |
| Dec 31, 2023 |
87.06% |
| Sep 30, 2023 |
-46.40% |
| Jun 30, 2023 |
22.23% |
| Mar 31, 2023 |
-27.18% |
| Dec 31, 2022 |
-91.03% |
| Sep 30, 2022 |
-370.51% |
| Jun 30, 2022 |
-26,515.43% |
| Mar 31, 2022 |
-4,053.55% |
| Dec 31, 2021 |
-257.96% |
| Sep 30, 2021 |
-71.05% |
| Jun 30, 2021 |
-100.31% |
